A role for the host in the roadmap to diabetes stem cell therapy by Soria, Bernat et al.
Bernat Soria,1,2 Eduard Montanya,2,3,4 Franz Martín,1,2 and Abdelkrim Hmadcha1,2
A Role for the Host in the Roadmap
to Diabetes Stem Cell Therapy
Diabetes 2016;65:1155–1157 | DOI: 10.2337/dbi16-0003
Stem cells represent an unlimited source for cell therapy
(1), and considerable efforts have been made to overcome
barriers to introducing this revolutionary therapy into
clinical practice. Briefly, the following actions must be
taken: 1) design in vitro differentiation strategies to gen-
erate either mature postmitotic b-cells or b-cell progeni-
tors that may be safely implanted into the host (e.g.,
without uncontrolled proliferation), 2) devise selection
methods to produce a pure b-cell population, 3) validate
standard characterization protocols to determine the real
differentiation stage of the cells ready to be transplanted,
4) obtain encapsulation devices to implant the cells, 5) de-
velop preclinical controls in representative animal models,
and 6) define cell-host interactions (for a recent review
see ref. 2).
A breakthrough for in vitro differentiation and selection
strategies was reported in Diabetes when it was shown for
the first time that the process was doable (3). A combination
of directed differentiation and gene-trapping strategies
succeeded in manufacturing insulin-producing cells de-
rived from rodent embryonic stem cells that normalized
blood glucose when implanted into streptozotocin (STZ)-
induced diabetic mice. Further reports improved the sys-
tem by introducing new differentiation strategies, such as
inhibiting sonic hedgehog or selecting cells expressing a
gene also expressed in islet progenitor cells (Nkx6.1) (4).
It was also shown that differentiated cells do not form
teratomas (4,5) and they mature 30 days after transplan-
tation (4). Subsequently, in vitro differentiation protocols
for human embryonic stem cells (hESCs) or induced plu-
ripotent stem cells succeeded in generating definitive en-
doderm (6–8). Numerous protocols have been published
that have yielded insulin-producing cells from pluripotent
stem cells (9–11). The full amount of contributions can-
not be properly acknowledged in the limited space of this
commentary. In vitro differentiation protocols reached a
milestone in 2014 when a patient with diabetes received a
subcutaneous implant of b-cell progenitors placed into
a biocompatible capsule that could eventually be re-
moved (Fig. 1) (12). This pilot study (clinical trial reg.
no. NCT02239354, clinicaltrials.gov), the first one ap-
proved in patients with diabetes by the U.S. Food and
Drug Administration (FDA), is currently recruiting partici-
pants with an estimated enrollment of 40 patients with
type 1 diabetes. No information has been made public
yet on the evolution of the implanted cells and patients.
In this issue, Bruin et al. (13) describe the impact of
thyroid dysregulation on the in vivo maturation of b-cell
progenitors derived from hESCs. Hypothyroidism was in-
duced in SCID beige mice using an iodine-deficient diet
with propylthiouracil. Hyperthyroidism was induced by
the addition of T4 to drinking water. Thyroid dysfunction
was described as “chronic” (for the duration of the study)
or “acute” (4 weeks posttransplantation). Euthyroid, hy-
pothyroid, and hyperthyroid mice received macroencapsu-
lated, hESC-derived pancreatic progenitor cell transplants.
Acute hyperthyroidism did not affect graft function, but
hypothyroidism inhibited the maturation of transplanted
islet progenitors and resulted in an increase in a- and
e-cells and fewer insulin-producing b-cells. Whereas acute
hypothyroidism transiently impaired human C-peptide se-
cretion, chronic hypothyroidism severely blunted human
C-peptide secretion and glucose-stimulated insulin secre-
tion and increased plasma glucagon levels. The results are
in line with recent in vitro studies that have investigated
the effects of thyroid hormones on the maturation of
human b-cells (14). In hESCs differentiated toward
b-cells, T3 enhanced the expression of the transcription
factor MAFA and increased insulin content and insulin
secretion in response to glucose (14). Bruin et al. (13)
clearly show an altered maturation of pancreatic progeni-
tors transplanted to hypothyroid mice. As grafts from
chronic hypothyroid mice contained less b-cells and more
a-cells, as well as reduced NKX2.2 expression, it may be
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Figure 1—Simplified model of pancreas organogenesis and differentiation and maturation strategies to obtain a functional b-cell. A:
Transcription factors required during the development of the islets of Langerhans. B: Sequential expression and temporal variation of
genes during in vitro differentiation protocols. C: Pancreatic progenitors to specialize into functional b-cells through maturation after
transplantation into STZ-induced hyperglycemic mice. D: Strategy for subcutaneous implantation of encapsulation devices with b-cell
progenitors that can mature inside the patient’s body and eventually control blood glucose and protect from immune insult. Alk5i, Alk5
receptor inhibitor; FGF, fibroblast growth factors; ITS, insulin transferrin selenium; N-Cys, N-acetyl cysteine; PP, pancreatic polypeptide
producing cells; R288, small-molecule inhibitor of the tyrosine kinase receptor AXL; RSV, Resveratrol; T3, thyroid hormone T3.
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that thyroid hormone deficiency could be tipping the bal-
ance in favor of a higher ARX expression that promotes
the expansion of a-cells at the expense of b- and d-cells.
Bruin et al. (13) recommend the transplantation of more
mature hESC-derived cells to minimize the maturation
period after transplantation. We suggest that transplan-
tation of MAFA-positive, hESC-derived cells could over-
come the effects of chronic hypothyroidism. However, at
this point the concept that reduced levels of thyroid hor-
mones may drive the differentiation of pancreatic progen-
itors cells toward a- and e-cell lineages at the expense
of b-cell formation, although attractive, requires further
study. On the other hand, a key observation is that these
progenitors may generate different islet cell types resulting
in a cell aggregate that could potentially better simulate
islet behavior.
The take-home message of the study by Bruin et al. is
that host milieu is determinant in the maturation process
of hESC-derived progenitor cells toward b-cells. Thus, re-
cipient candidates for this therapy may require additional
screening to fulfill the inclusion criteria. Relevant issues
that must be addressed in the field of stem cell therapy
in diabetes are 1) preimplantation maturation, and b-cell
selection strategies, 2) degree of maturation of differen-
tiated cells, 3) patient inclusion criteria, 4) safety of im-
plantation devices, 5) lack of long-term data, 6) role of
non–b-cells (a-cells, e-cells, etc.) in the islet physiology, 7)
vascularization of pseudoislet structures and the role of
endothelial cells, 8) development of fibrotic tissue around
the capsule restricting the access of oxygen and metabo-
lites, and 9) number of cells that should be implanted.
Regulatory authorities such as the FDA or the Euro-
pean Medicines Agency (EMA) have established that cells
used to treat diseases are “cellular medicaments” that
must fulfill the same criteria as small molecules and bio-
logicals (15). So far the only established cell therapy is
bone marrow transplantation. Cell therapy for diabetes is
still an experimental cellular medicament and has to fol-
low the well-established pattern of Phase I (safety), II
(efficacy and safety), and III (efficacy, efficiency, and
safety) trials to be approved by the regulatory agencies.
Our view is that there is a need to improve these cellular
medicaments by iterative preclinical and clinical research.
Because of the high cost of this development program,
we wonder whether these medicaments will be cost ef-
fective and affordable for the millions of people that
suffer from diabetes. In this sense, and given the enor-
mous task that the field faces, a private–public interna-
tional consortium with transparent rules may be a more
efficient way to reach a safe, effective, and affordable cure
for type 1 diabetes.
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